First in man study: Bcl-Xl_42-CAF^®09b vaccines in patients with locally advanced prostate cancer.

ABSTRACT:

Background

The B-cell lymphoma-extra-large (Bcl-XL) protein plays an important role in cancer cells' resistance to apoptosis. Pre-clinical studies have shown that vaccination with Bcl-XL-derived peptides can induce tumor-specific T cell responses that may lead to the elimination of cancer cells. Furthermore, pre-clinical studies of the novel adjuvant CAF^®09b have shown that intraperitoneal (IP) injections of this adjuvant can improve the activation of the immune system. In this study, patients with hormone-sensitive prostate cancer (PC) received a vaccine consisting of Bcl-XL-peptide with CAF^®09b as an adjuvant. The primary aim was to evaluate the tolerability and safety of IP and intramuscular (IM) administration, determine the optimal route of administration

SUBMITTER: Mork SK 

PROVIDER: S-EPMC10043415 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature